PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2008 2009
The prevalence of HIV, hepatitis B/C, HSV2, and tuberculosis in prisons is often disproportionately high
relative to the general population. Limited access to health care, unprotected sex, injection drug use,
tattooing, and other behaviors facilitate the transmission of blood-borne viruses in prison. Furthermore,
movement of prisoners, staff, and visitors in and out of prison increases the opportunity for transmission
among prisoners, staff, and the community. Little information exists on HIV prevalence, incidence, and
correlates of infection in Uganda prisons. Data collected in 1987 and 1996 found prevalence to be 15% and
26% respectively. HIV-related illnesses were the major cause of death among inmates in 2005. To develop
empirically-based HIV prevention and treatment programs for staff and prisoners of the UPS, this evaluation
will assess the prevalence/incidence of HIV, determine the prevalence of HBV, HCV, HSV-2, and TB, and
identify the correlates of prevalent/incident HIV infection by assessing knowledge, attitudes, beliefs, and
practices. The empirically-based data collected through this evaluation will provide the basic information
necessary to develop, test, and implement subsequent prevention and treatment initiatives that reduce the
risk of HIV transmission and provide access to and continuity of care among HIV-infected prisoners and
staff of the Uganda Prisons Services.
A single eligibility funding opportunity announcement (CDC-RFA-PS08-856) was published for FY2008 and
an application submitted by Uganda Prison Services. Funding allocated for FY2008 will be carried over to
FY2009 and therefore this project is now proposed to start in FY 2009.
In FY 2009, the following activities will be undertaken:
1. Development of serobehavioral and protocol, project infrastructure and staffing.
2. Obtain regulatory approval of serobehavioral survey protocol and instruments.
3. Conduct sero-behavioral survey. Prisoners and staff will participate in quantitative and qualitative
interviews, as well as provide blood samples for HIV, Hepatitis B/C virus, HSV2 testing. Study participants
will complete an Audio Computer Assisted Self Interview (ACASI) assessing knowledge, attitudes, beliefs,
and practices potentially related to HIV transmission. A HIV treatment and care needs assessment will also
be incorporated into these survey activities. CDC will train prison staff and inmates to use appropriate
survey-related technology. Blood will be drawn and transported to the CDC laboratory in Entebbe for testing
HSV 2, Hepatitis B/C and TB.
4. Evaluation Questions will include:
a) What are the current HIV treatment and prevention activities and challenges in the UPS?
b) Does the prevalence of HIV, STIs and TB among prisoners and staff of the UPS exceed that of the
general population?
c) What is the estimated incidence of HIV infection among prisoners and staff of the UPS as determined by
the BED assay?
d) What are the correlates of HIV infection among prisoners and staff of the UPS?
e) What is the prevalence of injection drug use, non-injection drug use, and sexual risk behavior among
prisoners and staff of the UPS?
5. Methods will include:
a) Process measures will be used to determine current treatment/prevention activities and challenges.
b) Cross-sectional survey design protocol will be developed and data collection will commence in FY09.
c) Multistage probability sampling will be used to randomly select a subset of prisons within the UPS (total
institutions=224), prisoners within selected institutions (total prisoners=27,000), and staff within the selected
institutions (total staff=4,171).
d) A 25% sample of prisoners will be randomly selected from the sampling frame composed of individuals
incarcerated within the five largest prisons and those institutions that were randomly selected.
e) Study participants will complete an Audio Computer-Assisted Self-Interview (ACASI) assessing
knowledge, attitudes, beliefs, and practices potentially related to HIV transmission/acquisition.
6. VCT:
a. 3375 prisoners and 521 staff in sampled prisons across the country will receive VCT in FY 09.
b. Ministry of Health protocols for routine HIV testing will be used to identify HIV-infected prisoners and staff
and to determine HIV prevalence among UPS institutions and administrative regions.
c. CD4 testing and the BED serologic incidence assay will be used to determine the prevalent or incident
status of HIV-positive specimens.
d. All testing will be conducted by the CDC laboratory in Entebbe.
New/Continuing Activity: Continuing Activity
Continuing Activity: 17050
Continued Associated Activity Information
Activity Activity ID USG Agency Prime Partner Mechanism Mechanism ID Mechanism Planned Funds
System ID System ID
17050 17050.08 HHS/Centers for To Be Determined 7632 7632.08 HIV/AIDS Prison
Disease Control & Survey
Prevention
Emphasis Areas
Gender
* Increasing gender equity in HIV/AIDS programs
Military Populations
Human Capacity Development
Estimated amount of funding that is planned for Human Capacity Development $105,792
Public Health Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery
Food and Nutrition: Commodities
Economic Strengthening
Education
Water
Table 3.3.03:
